Insider Trading Alert - JAZZ, ATRO And RHI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 14, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $95.00 to $17,134,950.00.

Highlighted Stocks Traded by Insiders:

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Berns Paul L, who is Director at Jazz Pharmaceuticals, sold 1,087 shares at $133.15 on Aug. 14, 2014. Following this transaction, the Director owned 3,993 shares meaning that the stake was reduced by 21.4% with the 1,087-share transaction.

Winningham Rick E, who is Director at Jazz Pharmaceuticals, sold 1,087 shares at $133.15 on Aug. 14, 2014. Following this transaction, the Director owned 14,150 shares meaning that the stake was reduced by 7.13% with the 1,087-share transaction.

Sohn Catherine A., who is Director at Jazz Pharmaceuticals, sold 1,731 shares at $133.15 on Aug. 14, 2014. Following this transaction, the Director owned 5,529 shares meaning that the stake was reduced by 23.84% with the 1,731-share transaction.

The shares most recently traded at $148.05, up $14.90, or 10.06% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 10,750
  • 12-Week # shares sold: 78,666
  • 24-Week # shares sold: 669,554

The average volume for Jazz Pharmaceuticals has been 869,400 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.7 billion and is part of the health care sector and drugs industry. Shares are up 13.96% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 111.8. Currently, there are 9 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Astronics (ATRO) - FREE Research Report

Peabody Mark, who is VP Astronics Advanced Electron at Astronics, sold 10,534 shares at $63.12 on Aug. 14, 2014. Following this transaction, the VP Astronics Advanced Electron owned 22,433 shares meaning that the stake was reduced by 31.95% with the 10,534-share transaction.

The shares most recently traded at $62.06, down $1.06, or 1.71% since the insider transaction. Historical insider transactions for Astronics go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 11,000
  • 24-Week # shares sold: 47,073

The average volume for Astronics has been 146,300 shares per day over the past 30 days. Astronics has a market cap of $895.3 million and is part of the industrial goods sector and aerospace/defense industry. Shares are up 25.24% year-to-date as of the close of trading on Thursday.

Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace and defense industries worldwide. It operates in two segments, Aerospace and Test Systems. The company has a P/E ratio of 34.0. Currently, there are 2 analysts who rate Astronics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATRO - FREE

TheStreet Quant Ratings rates Astronics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Astronics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Robert Half International (RHI) - FREE Research Report

Glass Robert W, who is Executive Vice President at Robert Half International, sold 4,028 shares at $49.38 on Aug. 14, 2014. Following this transaction, the Executive Vice President owned 377,912 shares meaning that the stake was reduced by 1.05% with the 4,028-share transaction.

The shares most recently traded at $49.05, down $0.33, or 0.66% since the insider transaction. Historical insider transactions for Robert Half International go as follows:

  • 4-Week # shares bought: 19,768
  • 4-Week # shares sold: 320,000
  • 12-Week # shares bought: 19,768
  • 12-Week # shares sold: 320,000
  • 24-Week # shares bought: 19,768
  • 24-Week # shares sold: 370,000

The average volume for Robert Half International has been 860,800 shares per day over the past 30 days. Robert Half International has a market cap of $6.8 billion and is part of the services sector and diversified services industry. Shares are up 18.17% year-to-date as of the close of trading on Thursday.

Robert Half International Inc. provides staffing and risk consulting services in North America, South America, Europe, Asia, and Australia. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 25.1. Currently, there are 8 analysts who rate Robert Half International a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RHI - FREE

TheStreet Quant Ratings rates Robert Half International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Robert Half International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes